Skip to main content
SpringerLink
Log in

Etanercept, infliximab and adalimumab have driven the growth in the spondyloarthropathy market, which reached nearly $US2 billion

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Decision Resources Inc.Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008. Media Release: 30 Apr 2009. Available from: URL: http://www.decisionresources.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Etanercept, infliximab and adalimumab have driven the growth in the spondyloarthropathy market, which reached nearly $US2 billion. Pharmacoecon. Outcomes News 579, 14 (2009). https://doi.org/10.2165/00151234-200905790-00034

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905790-00034

Keywords

Search

Navigation